# Integra LifeSciences Holdings Corporation (IART)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.31B  
**Price:** $17.09 (-4.53%)

> Integra LifeSciences Holdings Corporation is a global medical technology company specializing in innovative solutions for neurosurgery, tissue reconstruction, and ear, nose, and throat procedures. The company operates through two primary business segments: Codman Specialty Surgical, which manufactures neurosurgical instruments and products including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, and intracranial monitoring equipment; and Tissue Technologies, which develops regenerative medicine products for wound care, soft tissue repair, and dermal reconstruction. Integra's portfolio includes highly differentiated surgical instruments, implants, and regenerative matrices developed through decades of clinical evidence. The company distributes its products globally across more than 120 countries through a combination of direct sales forces, distributors, and wholesalers, with significant presence in North America and international markets. Founded in 1989 and headquartered in Princeton, New Jersey, Integra serves healthcare professionals in neurosurgery, neurocritical care, and specialized surgical fields where precision and clinical outcomes are paramount.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.64B | $832M | -$493M | -$516M | $-6.74 |
| 2024 | $1.61B | $882M | $28M | -$7M | $-0.09 |
| 2023 | $1.54B | $885M | $112M | $68M | $0.84 |
| 2022 | $1.56B | $970M | $239M | $181M | $2.16 |
| 2021 | $1.54B | $945M | $197M | $169M | $1.98 |
| 2020 | $1.37B | $851M | $151M | $134M | $1.57 |
| 2019 | $1.52B | $953M | $94M | $50M | $0.58 |
| 2018 | $1.47B | $901M | $111M | $61M | $0.72 |
| 2017 | $1.19B | $753M | $45M | $65M | $0.82 |
| 2016 | $992M | $643M | $115M | $75M | $0.94 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3.60B | $2.56B | $1.04B | $235M | $727M |
| 2024 | $4.04B | $2.49B | $1.55B | $246M | $760M |
| 2023 | $3.78B | $2.19B | $1.59B | $276M | $775M |
| 2022 | $3.89B | $2.09B | $1.80B | $457M | $775M |
| 2021 | $3.78B | $2.10B | $1.68B | $513M | $844M |
| 2020 | $3.62B | $2.10B | $1.51B | $470M | $878M |
| 2019 | $3.30B | $1.89B | $1.42B | $199M | $878M |
| 2018 | $3.11B | $1.73B | $1.38B | $139M | $900M |
| 2017 | $3.21B | $2.25B | $962M | $175M | — |
| 2016 | $1.81B | $968M | $840M | $102M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $50M | $81M | -$31M |
| 2024 | $129M | $104M | $25M |
| 2023 | $140M | $67M | $73M |
| 2022 | $264M | $42M | $222M |
| 2021 | $312M | $48M | $264M |
| 2020 | $204M | $39M | $165M |
| 2019 | $231M | $70M | $162M |
| 2018 | $200M | $78M | $122M |
| 2017 | $115M | $44M | $71M |
| 2016 | $116M | $47M | $69M |
| 2015 | $105M | $33M | $71M |
| 2014 | $84M | $38M | $45M |
| 2013 | $53M | $42M | $11M |
| 2012 | $59M | $69M | -$10M |
| 2011 | $104M | $38M | $66M |

Source: [CompaniesByCap](https://companiesbycap.com/company/IART)